Please provide your email address to receive an email when new articles are posted on . Data came from the FDA Adverse Event Reporting System from 2004 to 2024. Omalizumab had significant associations ...
Chances are, you may know a family living with food allergies. Food allergies are more prevalent than many realize, particularly among children in the United States. In 2024, an estimated 3.4 million ...
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Findings showed equivalent efficacy in change from baseline in weekly itch severity score between omalizumab-igec 300mg and Xolair 300mg. The Food and Drug Administration (FDA) has approved Omlyclo ® ...
SAN DIEGO — Treatment options for food allergies are expanding, but interpreting research findings for individualized clinical care is tricky. That theme emerged at the American Academy of Allergy, ...
The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory condition in the U.S., drugmaker Celltrion announced Monday. The ...
Participants in the OUtMATCH trial are allergic to peanuts and at least two other foods among milk, eggs, wheat, cashews, walnuts and hazelnuts. Credit: NIAID The high rate of side effects from oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback